Peer-reviewed veterinary case report
Long-term safety of Credelio Quattro chewable tablets for dogs
By Riggs, Kari L et al.·Published in Parasites & vectors·2025·Elanco Animal Health, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Long-term safety of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), a novel orally administered combination endectocide for dogs.
- Species:
- dog
Plain-English summary
A group of healthy 8-week-old Beagle puppies was given a new chewable tablet called Credelio Quattro, which helps protect against parasites, to see if it was safe for long-term use. The puppies received the treatment every month for several months, and while some experienced mild side effects like discolored poop, diarrhea, and vomiting, there were no serious health issues noted. Overall, the study found that Credelio Quattro is safe for dogs when given at the recommended dose, making it a good option for monthly parasite prevention.
People also search for: dog parasite prevention · Credelio Quattro side effects · Beagle vomiting after medication
Abstract
BACKGROUND: The combination of lotilaner, moxidectin, praziquantel, and pyrantel pamoate (Credelio Quattro) is a novel systemic endectocide that provides month-long effectiveness in dogs after a single oral treatment. The safety of Credelio Quattro flavored chewable tablets was investigated when administered orally at the upper end of the recommended dosage range (20-41 mg/kg lotilaner, 0.02-0.04 mg/kg moxidectin, 5-10 mg/kg praziquantel, and 5-10 mg/kg pyrantel) and multiples thereof when administered long term. METHODS: The study was randomized and blinded, with parallel groups beginning in healthy 8-week-old Beagle dogs and continuing until they reached adulthood. A total of 32 dogs were randomized among four groups (8 dogs/group) to nontreated controls or to treated groups at target doses of 1×, 3×, or 5× the maximum dose. Treatment was administered on nine occasions to dogs in a fed state every 4 weeks, with the control group receiving placebo tablets. Assessment of safety was based on regular health observations, complete physical/neurological examinations, food consumption, clinical pathology evaluations (hematology, clinical chemistry, and urinalysis), body weight, and macroscopic and microscopic examinations of collected tissues. RESULTS: Credelio Quattro did not induce any serious treatment-related adverse effects based on health observations, physical/neurological examinations, food consumption, clinical pathology, body weight, or macroscopic and microscopic examinations. The only non-serious treatment-related effects of Credelio Quattro were a dose-dependent increase in the frequency of discolored feces, diarrhea, and vomiting (including hypersalivation associated with vomiting in two of the 5× dogs). CONCLUSIONS: This study demonstrates that Credelio Quattro exhibits a wide safety margin when administered monthly to puppies and dogs at the maximum recommended commercial dose, with only transient gastrointestinal symptoms similar to other oral antiparasitic products observed. Therefore, Credelio Quattro may be safely administered to dogs each month in accordance with the approved label.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41398970/